Abstract
Despite tremendous efforts in preclinical research over the last decades, the clinical translation of therapeutic angiogenesis to grow stable and functional blood vessels in patients with ischemic diseases continues to prove challenging. In this mini review, we briefly present the current main approaches applied to improve pro-angiogenic therapies. Specific examples from research on therapeutic cardiac angiogenesis and arteriogenesis will be discussed, and finally some suggestions for future therapeutic developments will be presented.
Highlights
Over the last 15 years, the use of anti-angiogenic agents to inhibit blood vessel growth has clearly established its ‘raison d’être’ in the treatment of human diseases, including multiple types of cancer, and vascular retinopathies (1)
We briefly present the current main approaches applied to improve pro-angiogenic therapies
It seems likely that, similar to the requirement of most antiangiogenic agents to be used in combination with chemotherapy or other tumor cell-targeting drugs in cancer patients, pro-angiogenic therapies should be combined with pharmacological treatments that reduce vascular endothelial dysfunction (25)
Summary
Over the last 15 years, the use of anti-angiogenic agents to inhibit blood vessel growth has clearly established its ‘raison d’être’ in the treatment of human diseases, including multiple types of cancer, and vascular retinopathies (1). Despite tremendous efforts in preclinical research over the last decades, the clinical translation of therapeutic angiogenesis to grow stable and functional blood vessels in patients with ischemic diseases continues to prove challenging.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
